VeriSee AMD

VeriSee AMD is an AI-assisted screening software that analyzes fundus images to identify high-risk patients with age-related macular degeneration (AMD). Targeting individuals aged 50 and above, the software provides referral recommendations based on the AREDS severity scale, achieving 95% accuracy with 90% sensitivity and 96% specificity in clinical validation.

Product Overview

Age-related macular degeneration represents a leading cause of severe vision loss among adults over 50, accounting for nearly 50% of elderly blindness cases in the United States with annual healthcare expenditures exceeding $500 million. VeriSee AMD addresses the challenge of early AMD detection by enabling healthcare professionals without specialized ophthalmology training to conduct effective screening.

The software’s AI model, trained on fundus images labeled by retina specialists, identifies patients meeting AREDS (Age-Related Eye Disease Study) level 3 or above criteria. This threshold indicates intermediate to advanced AMD stages requiring ophthalmologist referral for further evaluation and potential treatment intervention.

Key Features

Designed to screen adults over 50 for age-related macular degeneration, VeriSee AMD classifies fundus images at AREDS Level 3+ with 95% accuracy and 96% specificity.

• AREDS Classification: Automatically categorizes AMD severity based on standardized clinical scale
• High Accuracy: 95% overall accuracy with 90% sensitivity and 96% specificity
• Batch Analysis: Processes up to 1,000 images simultaneously for population screening programs
• Offline Capability: Functions without network connection for patient data security
• Rapid Output: Delivers referral recommendations within seconds

Technical Specifications

At 95% accuracy with 90% sensitivity, VeriSee AMD processes up to 1,000 fundus images per batch offline, flagging patients requiring ophthalmologist referral.

Clinical Applications

VeriSee AMD serves healthcare facilities conducting geriatric health screenings, senior care centers, and primary care clinics managing elderly populations. The software integrates with standard fundus cameras to provide immediate AMD risk assessment during routine health examinations.

Early AMD detection enables timely intervention before disease progression to critical stages that may result in irreversible vision loss. The software’s high specificity minimizes unnecessary specialist referrals while maintaining sensitivity for clinically significant cases.

Regulatory Status

Market Context

VeriSee AMD complements the VeriSee DR system, together forming a broad AI-powered ophthalmology screening platform. Both products operate on the same hardware platform—Acer AI PCs with Intel Core Ultra processors—enabling healthcare facilities to address multiple eye conditions with a single system investment.

The software received the 2022 Taiwan Innovation Award (Silver) in recognition of its contribution to preventive healthcare technology.

Frequently Asked Questions

What age group is VeriSee AMD designed for?

VeriSee AMD is designed for screening adults aged 50 and above, as age represents the primary risk factor for AMD development.

How does VeriSee AMD classify macular degeneration severity?

The software uses the AREDS (Age-Related Eye Disease Study) classification system, flagging patients who meet Level 3 or above criteria for referral to ophthalmology specialists.

Can VeriSee AMD and VeriSee DR run on the same system?

Yes, both VeriSee AMD and VeriSee DR can operate on the same Acer AI PC platform, allowing healthcare facilities to conduct eye screening for both diabetic retinopathy and macular degeneration.